MediWound Ltd. (NASDAQ:MDWD) Q4 2022 Earnings Conference Call March 16, 2023 8:30 AM ET
Company Participants
Monique Kosse - LifeSci Advisors, IR
Ofer Gonen - Chief Executive Officer
Boaz Gur-Lavie - Chief Financial Officer
Conference Call Participants
Josh Jennings - TD Cowen
Francois Brisebois - Oppenheimer
Swayampakula Ramakanth - H.C. Wainwright
Michael Okunewitch - Maxim Group
Operator
Good day. And welcome to MediWound’s Fourth Quarter and Year End 2022 Earnings Call. Today’s conference is being recorded.
At this time, I would like to turn the conference over to Monique Kosse of LifeSci Advisors. Monique, please go ahead.
Monique Kosse
Thank you, Operator, and welcome, everyone. Earlier today, MediWound issued a press release announcing financial results for the fourth quarter and year ended December 31, 2022. You may access that release on the company’s website under the Investors tab.
With us today are Ofer Gonen, Chief Executive Officer of MediWound; and Boaz Gur-Lavie, Chief Financial Officer. Following our prepared remarks, we will open the call for Q&A.
Before we begin, I would like to remind everyone that statements made during this call, including the Q&A session, relating to MediWound’s expected future performance, future business prospects or future events or plans are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995.
Although the company believes the expectations reflected in such forward-looking statements are based upon reasonable assumptions, actual outcomes and results are subject to risks and uncertainties and could differ materially from those forecast due to the impact of many factors beyond the control of MediWound.
The company assumes no obligation to update or supplement any forward-looking statements, whether as a result of new information, future events or otherwise. Participants are directed to cautionary notes set forth in today’s press release, as well as the Risk Factors set forth in MediWound’s annual report filed with the SEC for factors that could cause actual results to differ materially from those anticipated in the forward-looking statements.
The conference call is the property of MediWound and any recording or rebroadcast is expressly prohibited without the written consent of MediWound.
Now, I’d like to turn the call over to Ofer Gonen, Chief Executive Officer of MediWound. Ofer?
Ofer Gonen
Thank you, Monique, and good morning, everyone. It is my pleasure to welcome you to our conference call. I am excited to be here today to discuss the remarkable company achievements in the fourth quarter and throughout 2022. We have made important achievements in all of our programs, positioning ourselves to become a global biopharmaceutical company.